AP2213A - Muscarinic acetylcholine receptor antagonists. - Google Patents

Muscarinic acetylcholine receptor antagonists.

Info

Publication number: AP2213A
Authority: AP; ARIPO
Prior art keywords: receptor antagonists; acetylcholine receptor; muscarinic acetylcholine; muscarinic; antagonists
Prior art date: 2004-04-27

Application number

AP2006003746A

Other languages

English (en)

Other versions

AP2006003746A0 (en

Inventor

Dramane Ibrahim Laine

Michael R Palovich

Brent W Mccleland

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-27

Filing date

2005-04-27

Publication date

2011-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-27 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2006-10-31 Publication of AP2006003746A0 publication Critical patent/AP2006003746A0/xx

2011-03-01 Application granted granted Critical

2011-03-01 Publication of AP2213A publication Critical patent/AP2213A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)

AP2006003746A 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists. AP2213A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US56562304P	2004-04-27	2004-04-27
PCT/US2005/014386 WO2005104745A2 (fr)	2004-04-27	2005-04-27	Antagonistes des récepteurs muscariniques de l'acétylcholine

Publications (2)

Publication Number	Publication Date
AP2006003746A0 AP2006003746A0 (en)	2006-10-31
AP2213A true AP2213A (en)	2011-03-01

Family

ID=35242158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2006003746A AP2213A (en)	2004-04-27	2005-04-27	Muscarinic acetylcholine receptor antagonists.

Country Status (38)

Country	Link
US (9)	US7498440B2 (fr)
EP (3)	EP1740177B1 (fr)
JP (2)	JP5014121B2 (fr)
KR (2)	KR101037026B1 (fr)
CN (2)	CN1976701A (fr)
AP (1)	AP2213A (fr)
AR (1)	AR050902A1 (fr)
AU (1)	AU2005237576B2 (fr)
BE (1)	BE2014C063I2 (fr)
BR (1)	BRPI0510170B8 (fr)
CA (2)	CA2755954C (fr)
CY (3)	CY1113196T1 (fr)
DK (2)	DK2570128T3 (fr)
EA (2)	EA021994B1 (fr)
EC (1)	ECSP066940A (fr)
ES (2)	ES2600405T3 (fr)
HK (1)	HK1102423A1 (fr)
HR (2)	HRP20120832T1 (fr)
HU (2)	HUE031304T2 (fr)
IL (1)	IL178152A (fr)
LT (1)	LT2570128T (fr)
LU (1)	LU92565I2 (fr)
MA (1)	MA28631B1 (fr)
MX (1)	MXPA06012405A (fr)
MY (1)	MY144753A (fr)
NL (1)	NL300694I2 (fr)
NO (3)	NO338959B1 (fr)
NZ (1)	NZ549997A (fr)
PE (1)	PE20060259A1 (fr)
PL (2)	PL2570128T3 (fr)
PT (2)	PT2570128T (fr)
SG (1)	SG186597A1 (fr)
SI (2)	SI1740177T1 (fr)
TW (1)	TWI363759B (fr)
UA (1)	UA95768C2 (fr)
UY (1)	UY28871A1 (fr)
WO (1)	WO2005104745A2 (fr)
ZA (1)	ZA200608565B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR045914A1 (es) *	2003-07-17	2005-11-16	Glaxo Group Ltd	Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
UY28567A1 (es) *	2003-10-17	2005-05-31	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
PE20050489A1 (es) *	2003-11-04	2005-09-02	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
JP2007528420A (ja) *	2004-03-11	2007-10-11	グラクソ　グループ　リミテッド	新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005094251A2 (fr) *	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur muscarinique a l'acetylcholine m3
US7384946B2 (en) *	2004-03-17	2008-06-10	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
DE602005009158D1 (de) *	2004-04-05	2008-10-02	Samaritan Pharmaceuticals Inc	Anti-hiv-chinuklidinverbindungen
TWI363759B (en)	2004-04-27	2012-05-11	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
EP1747219A4 (fr) *	2004-05-13	2010-05-26	Glaxo Group Ltd	Domaine de l'invention antagonistes récepteurs d'acétyle choline muscarinique
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
US7932247B2 (en) *	2004-11-15	2011-04-26	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
JP2009503099A (ja) *	2005-08-02	2009-01-29	グラクソグループリミテッド	Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
JP2009504768A (ja) *	2005-08-18	2009-02-05	グラクソグループリミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
AU2007242851A1 (en)	2006-04-20	2007-11-01	Glaxo Group Limited	Novel compounds
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
CA2659539A1 (fr)	2006-08-01	2008-02-07	Glaxo Group Limited	Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de pde4
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
PE20091563A1 (es)	2008-02-06	2009-11-05	Glaxo Group Ltd	Farmacoforos duales - antagonistas muscarinicos de pde4
CL2009000248A1 (es)	2008-02-06	2009-09-11	Glaxo Group Ltd	Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas
UY31637A1 (es)	2008-02-06	2009-08-03		Farmacoforos duales-antagonistas muscarinicos de pde4
EP2280946B1 (fr)	2008-06-05	2016-02-10	Glaxo Group Limited	Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases
JP5502077B2 (ja)	2008-06-05	2014-05-28	グラクソグループリミテッド	新規な化合物
WO2010094643A1 (fr)	2009-02-17	2010-08-26	Glaxo Group Limited	Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
HRP20241000T3 (hr)	2009-02-26	2024-10-25	Glaxo Group Limited	Farmaceutske formulacije koje sadrže 4-{(1r)-2-[(6-{2-[(2,6-diklorobenzil)oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenol
JP5656880B2 (ja)	2009-03-09	2015-01-21	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
EP2406249A1 (fr)	2009-03-10	2012-01-18	Glaxo Group Limited	Dérivés d'indole comme inhibiteurs de ikk2
EP2408769A1 (fr)	2009-03-17	2012-01-25	Glaxo Group Limited	Dérivés de pyrimidine utilisés comme inhibiteurs de ltk
CA2759476C (fr)	2009-04-30	2018-10-09	Julie Nicole Hamblin	Composes novateurs
WO2011029896A1 (fr)	2009-09-11	2011-03-17	Glaxo Group Limited	Procedes de preparation d'antagonistes des recepteurs cholinergiques muscariniques
GB0921075D0 (en) *	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
JP2013512878A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	新規化合物
EP2507223A1 (fr)	2009-12-03	2012-10-10	Glaxo Group Limited	Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases
WO2011067366A1 (fr)	2009-12-03	2011-06-09	Glaxo Group Limited	Dérivés d'indazole comme inhibiteurs des pi3-kinases
US8742131B2 (en) *	2010-01-28	2014-06-03	Theron Pharmaceuticals, Inc.	7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (fr)	2010-03-11	2011-09-15	Glaxo Group Limited	Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
CN102946868B (zh) *	2010-06-22	2014-10-29	奇斯药制品公司	包含抗毒蕈碱药的干粉制剂
RS54286B1 (en)	2010-09-08	2016-02-29	Glaxosmithkline Intellectual Property Development Limited	POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide
WO2012035055A1 (fr)	2010-09-17	2012-03-22	Glaxo Group Limited	Nouveaux composés
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
KR20140041699A (ko) *	2011-06-08	2014-04-04	글락소 그룹 리미티드	우메클리디늄 및 코르티코스테로이드를 포함하는 조합물
AU2012266540A1 (en)	2011-06-08	2014-01-09	Glaxo Group Limited	Dry powder inhaler compositions comprising umeclidinium
CA2869849A1 (fr)	2012-04-13	2013-10-17	Glaxosmithkline Intellectual Property Development Limited	Particules agregees comprenant des particules de medicament nanoparticulaires de bromure d'umeclidinium, de trifenatate de vilanterol et de furoate de fluticasone
RU2502743C1 (ru) *	2012-08-03	2013-12-27	Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России)	Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
CA2881935A1 (fr) *	2012-08-15	2014-02-20	Glaxo Group Limited	Procede de preparation d'un intermediaire de carboxylate de 1-(2-haolethyle) -4-piperidine utile dans la synthese du bromure d'umeclidinium
GB201222679D0 (en) *	2012-12-17	2013-01-30	Glaxo Group Ltd	Pharmaceutical combination products
RU2641285C2 (ru) *	2013-07-13	2018-01-17	Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд	Соединения хинина, способ их получения и их медицинское применение
SG11201600045UA (en) *	2013-07-30	2016-02-26	Glaxosmithkline Ip Dev Ltd	Topical compositions for treatment of excessive sweating and methods of use thereof
JP6475707B2 (ja)	2013-10-17	2019-02-27	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
WO2015055690A1 (fr)	2013-10-17	2015-04-23	Glaxosmithkline Intellectual Property Development Limited	Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
MX2016014859A (es)	2014-05-12	2017-06-27	Glaxosmithkline Intellectual Property (No 2) Ltd	Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
ES2959699T3 (es)	2014-05-28	2024-02-27	Glaxosmithkline Ip Dev Ltd	Furoato de fluticasona en el tratamiento de la EPOC
US10023535B2 (en)	2014-11-03	2018-07-17	Olon S.P.A.	Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko)	2015-04-27	2016-04-18	주식회사 대웅제약	신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) *	2015-10-23	2016-04-06	安徽德信佳生物医药有限公司	一种芜地溴铵的制备方法
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN107200734B (zh) *	2016-03-18	2019-12-24	益方生物科技（上海）有限公司	奎宁环衍生物及其制备方法和用途
EP3248970A1 (fr)	2016-05-27	2017-11-29	Zentiva K.S.	Les formes du bromure d'uméclidinium
EP3497100A1 (fr)	2016-08-08	2019-06-19	GlaxoSmithKline Intellectual Property Development Limited	Composés chimiques
PT109740B (pt) *	2016-11-14	2020-07-30	Hovione Farmaciencia Sa	Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (fr) *	2017-03-08	2018-09-13	Gbr Laboratories Pvt. Ltd	Procédé de préparation de bromure d'uméclidinium et de ses intermédiaires
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
IT201700058796A1 (it) *	2017-05-30	2018-11-30	Olon Spa	Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN108558860B (zh) *	2018-06-04	2020-12-25	成都伊诺达博医药科技有限公司	一种合成芜地溴铵的方法
WO2020047225A1 (fr)	2018-08-30	2020-03-05	Theravance Biopharma R&D Ip, Llc	Procédés de traitement de bronchopneumopathie chronique obstructive
PT115583B (pt)	2019-06-17	2022-05-02	Hovione Farm S A	Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) *	2020-03-13	2021-09-14	诺华股份有限公司	硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
BR112022019245A2 (pt)	2020-03-26	2022-11-16	Glaxosmithkline Ip Dev Ltd	Inibidores de catepsina para prevenir ou tratar infecções virais
CN111484445B (zh) *	2020-04-21	2021-05-18	广东莱佛士制药技术有限公司	分离纯化高纯度乌美溴铵的中间体的方法
AU2021264829B2 (en) *	2020-04-26	2024-02-01	Beijing Showby Pharmaceutical Co., Ltd.	Crystal of M receptor antagonist as well as preparation method therefor and application thereof
CA3192236A1 (fr)	2020-09-10	2022-03-17	Tony Lahoutte	Fragment d'anticorps contre fap
CN112479983B (zh) *	2020-11-25	2022-07-12	江苏豪森药业集团有限公司	乌美溴铵中间体及其制备方法
PT117440B (pt)	2021-09-03	2024-04-26	Hovione Farm S A	Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (fr)	2022-04-22	2023-10-26	Precirix N.V.	Anticorps radiomarqué amélioré
WO2023213801A1 (fr)	2022-05-02	2023-11-09	Precirix N.V.	Pré-ciblage
WO2024251812A1 (fr)	2023-06-07	2024-12-12	Pharmazell Gmbh	Procédé de préparation d'un intermédiaire de bromure d'uméclidinium

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2800481A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de)	1967-06-08	1972-04-25	Siemens Ag	Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en)	1967-08-08	1971-08-11	Fisons Pharmaceuticals Ltd	Pharmaceutical composition
GB1230087A (fr)	1967-08-17	1971-04-28
GB1381872A (en)	1971-06-22	1975-01-29	Fisons Ltd	Pharmaceutical compositions for inhalation
CY1308A (en)	1979-12-06	1985-12-06	Glaxo Group Ltd	Device for dispensing medicaments
DE3274065D1 (de)	1981-07-08	1986-12-11	Draco Ab	Powder inhalator
IN160851B (fr)	1982-10-08	1987-08-08	Glaxo Group Ltd
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
NL8601949A (nl)	1985-07-30	1987-02-16	Glaxo Group Ltd	Inrichtingen voor het toedienen van medicamenten aan patienten.
IT1204826B (it)	1986-03-04	1989-03-10	Chiesi Farma Spa	Composizioni farmaceutiche per inalazione
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
US5780466A (en)	1995-01-30	1998-07-14	Sanofi	Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
JP2001505576A (ja)	1996-12-02	2001-04-24	ジョージタウンユニバーシティ	トロパン誘導体類及びそれらの合成方法
US6248752B1 (en)	1998-02-27	2001-06-19	Charles Duane Smith	Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en)	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1353919B1 (fr) *	2000-12-28	2006-07-26	Almirall Prodesfarma AG	Nouveaux derives de quinuclidine et compositions medicinales contenant ces derniers
EP1438309A1 (fr)	2001-10-17	2004-07-21	Ucb, S.A.	Derives de quinuclidine, leurs procedes de preparation, et leurs utilisations en tant qu'inhibiteurs de recepteur muscarinique m2 et/ou m3
CA2466344A1 (fr) *	2001-11-09	2003-05-22	Pharmacia & Upjohn Company	Composes heterocycliques fusionnes avec un groupe phenyl-azabicyclique et leur utilisation en tant que ligands de recepteur nachr alpha 7
IL162596A0 (en) *	2001-12-20	2005-11-20	S A L V A T Lab Sa	1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
US6696462B2 (en) *	2002-01-31	2004-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es)	2002-04-16	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirrolidinio.
ES2204295B1 (es) *	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de quinuclidina-amida.
UY27927A1 (es)	2002-08-06	2003-12-31	Glaxo Group Ltd	Antagonistas del receptor muscarínico m3 de acetilcolina
EP1613307A4 (fr)	2003-04-07	2008-03-12	Glaxo Group Ltd	Antagonistes du recepteur muscarinique m sb 3 /sb de l'acetylcholine
AR048573A1 (es)	2003-07-17	2006-05-10	Glaxo Group Ltd	Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
AR045914A1 (es) *	2003-07-17	2005-11-16	Glaxo Group Ltd	Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
AR045913A1 (es)	2003-07-17	2005-11-16	Glaxo Group Ltd	Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
MY143366A (en)	2003-10-14	2011-04-29	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
UY28567A1 (es)	2003-10-17	2005-05-31	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
PE20050489A1 (es)	2003-11-04	2005-09-02	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
CA2543858C (fr)	2003-11-21	2014-04-15	Theravance, Inc.	Composes ayant une activite agoniste de recepteur adrenergique beta 2 et antagoniste de recepteur muscarinique
AR046783A1 (es)	2003-12-03	2005-12-21	Glaxo Group Ltd	Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima
UY28645A1 (es)	2003-12-03	2005-06-30	Glaxo Group Ltd	Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en)	2004-01-13	2005-11-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
WO2005086873A2 (fr)	2004-03-11	2005-09-22	Glaxo Group Limited	Nouveaux antagonistes du recepteur d'acetylcholine muscarinique m3
JP2007528420A (ja)	2004-03-11	2007-10-11	グラクソ　グループ　リミテッド	新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185090A1 (en)	2004-03-17	2007-08-09	Jakob Busch-Petersen	Muscarinic acetylchoine receptor antagonists
US7384946B2 (en)	2004-03-17	2008-06-10	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (fr)	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur muscarinique a l'acetylcholine m3
WO2005094835A1 (fr)	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1732923A2 (fr)	2004-04-07	2006-12-20	Glaxo Group Limited	Antagonistes du recepteur muscarinique de l'acetylcholine
TWI363759B (en)	2004-04-27	2012-05-11	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
EP1747219A4 (fr)	2004-05-13	2010-05-26	Glaxo Group Ltd	Domaine de l'invention antagonistes récepteurs d'acétyle choline muscarinique
AR048976A1 (es)	2004-05-28	2006-06-14	Glaxo Group Ltd	Compuesto derivado de alcohol terciario de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
JP2008505118A (ja)	2004-06-30	2008-02-21	グラクソ　グループ　リミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
US20070293531A1 (en)	2004-08-05	2007-12-20	Jakob Busch-Petersen	Muscarinic Acetycholine Receptor Antagonists
WO2006017767A2 (fr)	2004-08-06	2006-02-16	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique
WO2006050239A2 (fr)	2004-10-29	2006-05-11	Glaxo Group Limited	Antagonistes des recepteurs de l'acetylcholine muscarinique
WO2006055503A2 (fr)	2004-11-15	2006-05-26	Glaxo Group Limited	Nouveaux antagonistes du recepteur d'acetylcholine muscarinique m3
US7932247B2 (en)	2004-11-15	2011-04-26	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es)	2004-12-06	2006-10-14	Smithkline Beecham Corp	Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es)	2004-12-06	2006-10-08	Smithkline Beecham Corp	Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065755A2 (fr)	2004-12-13	2006-06-22	Glaxo Group Limited	Sels d'ammonium quaternaire d'amines heteroaromatiques fusionnees utilises comme nouveaux antagonistes du recepteur de l'acetylcholine muscarinique
WO2006065788A2 (fr)	2004-12-13	2006-06-22	Glaxo Group Limited	Nouveaux antagonistes du recepteur muscarinique de l'acetylcholine
WO2007018514A1 (fr)	2005-07-28	2007-02-15	Glaxo Group Limited	Nouveaux antagonistes récepteurs d’acétylcholine muscarinique m3
WO2007018508A1 (fr)	2005-07-28	2007-02-15	Glaxo Group Limited	Nouveaux antagonistes du récepteur muscarinique m3 de l’acétylcholine
JP2009503099A (ja)	2005-08-02	2009-01-29	グラクソグループリミテッド	Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2007016650A2 (fr)	2005-08-02	2007-02-08	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique m3
JP2009504768A (ja)	2005-08-18	2009-02-05	グラクソグループリミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
GB0921075D0 (en) *	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents

2005
- 2005-04-25 TW TW094113034A patent/TWI363759B/zh active
- 2005-04-25 MY MYPI20051806A patent/MY144753A/en unknown
- 2005-04-25 AR ARP050101627A patent/AR050902A1/es active IP Right Grant
- 2005-04-25 PE PE2005000457A patent/PE20060259A1/es active IP Right Grant
- 2005-04-25 UY UY28871A patent/UY28871A1/es not_active Application Discontinuation
- 2005-04-27 ES ES12170402.7T patent/ES2600405T3/es active Active
- 2005-04-27 LT LTEP12170402.7T patent/LT2570128T/lt unknown
- 2005-04-27 ES ES05746609.6T patent/ES2392848T4/es active Active
- 2005-04-27 PL PL12170402T patent/PL2570128T3/pl unknown
- 2005-04-27 EA EA201100019A patent/EA021994B1/ru not_active IP Right Cessation
- 2005-04-27 PT PT121704027T patent/PT2570128T/pt unknown
- 2005-04-27 SI SI200531605T patent/SI1740177T1/sl unknown
- 2005-04-27 EA EA200601991A patent/EA015033B1/ru not_active IP Right Cessation
- 2005-04-27 EP EP05746609A patent/EP1740177B1/fr active Active
- 2005-04-27 SI SI200532099A patent/SI2570128T1/sl unknown
- 2005-04-27 NZ NZ549997A patent/NZ549997A/en unknown
- 2005-04-27 PT PT05746609T patent/PT1740177E/pt unknown
- 2005-04-27 HU HUE12170402A patent/HUE031304T2/hu unknown
- 2005-04-27 US US11/568,330 patent/US7498440B2/en active Active
- 2005-04-27 KR KR1020067022276A patent/KR101037026B1/ko active Protection Beyond IP Right Term
- 2005-04-27 AP AP2006003746A patent/AP2213A/xx active
- 2005-04-27 DK DK12170402.7T patent/DK2570128T3/en active
- 2005-04-27 EP EP12170402.7A patent/EP2570128B1/fr active Active
- 2005-04-27 BR BRPI0510170A patent/BRPI0510170B8/pt active IP Right Grant
- 2005-04-27 CN CNA2005800215360A patent/CN1976701A/zh active Pending
- 2005-04-27 AU AU2005237576A patent/AU2005237576B2/en active Active
- 2005-04-27 CA CA2755954A patent/CA2755954C/fr active Active
- 2005-04-27 KR KR1020117001909A patent/KR101152032B1/ko active IP Right Grant
- 2005-04-27 PL PL05746609T patent/PL1740177T3/pl unknown
- 2005-04-27 SG SG2012087052A patent/SG186597A1/en unknown
- 2005-04-27 CN CN2010105580787A patent/CN102040602A/zh active Pending
- 2005-04-27 UA UAA200611253A patent/UA95768C2/ru unknown
- 2005-04-27 JP JP2007510915A patent/JP5014121B2/ja active Active
- 2005-04-27 MX MXPA06012405A patent/MXPA06012405A/es active IP Right Grant
- 2005-04-27 EP EP16177012.8A patent/EP3111936A1/fr not_active Withdrawn
- 2005-04-27 DK DK05746609.6T patent/DK1740177T3/da active
- 2005-04-27 WO PCT/US2005/014386 patent/WO2005104745A2/fr active Application Filing
- 2005-04-27 CA CA2564742A patent/CA2564742C/fr active Active
2006
- 2006-09-18 IL IL178152A patent/IL178152A/en active Protection Beyond IP Right Term
- 2006-10-13 ZA ZA2006/08565A patent/ZA200608565B/en unknown
- 2006-10-20 EC EC2006006940A patent/ECSP066940A/es unknown
- 2006-10-31 MA MA29426A patent/MA28631B1/fr unknown
- 2006-11-24 NO NO20065417A patent/NO338959B1/no active Protection Beyond IP Right Term
2007
- 2007-06-27 HK HK07106891.0A patent/HK1102423A1/xx unknown
- 2007-07-09 US US11/774,867 patent/US7488827B2/en active Active
2009
- 2009-01-14 US US12/353,436 patent/US8183257B2/en active Active
2012
- 2012-02-22 US US13/401,890 patent/US8309572B2/en active Active
- 2012-04-13 JP JP2012092339A patent/JP5398871B2/ja active Active
- 2012-09-26 US US13/627,007 patent/US8575347B2/en active Active
- 2012-10-15 HR HRP20120832TT patent/HRP20120832T1/hr unknown
- 2012-10-17 CY CY20121100965T patent/CY1113196T1/el unknown
2013
- 2013-10-14 US US14/052,816 patent/US8853404B2/en active Active
2014
- 2014-09-04 US US14/476,940 patent/US9045469B2/en active Active
- 2014-09-26 HU HUS1400053C patent/HUS1400053I1/hu unknown
- 2014-10-02 BE BE2014C063C patent/BE2014C063I2/fr unknown
- 2014-10-02 NL NL300694C patent/NL300694I2/nl unknown
- 2014-10-02 LU LU92565C patent/LU92565I2/fr unknown
- 2014-10-03 CY CY2014043C patent/CY2014043I1/el unknown
2015
- 2015-05-08 US US14/707,543 patent/US9144571B2/en active Active
- 2015-09-10 US US14/849,775 patent/US20160002220A1/en not_active Abandoned
2016
- 2016-10-10 CY CY20161101008T patent/CY1118082T1/el unknown
- 2016-10-25 HR HRP20161385TT patent/HRP20161385T1/hr unknown
2017
- 2017-05-04 NO NO2017018C patent/NO2017018I2/no unknown
- 2017-05-04 NO NO2017017C patent/NO2017017I1/no unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IKEDA, K et al. M3 receptor angagonism by the novel antimuscarinio agent solifenacin in the urinary bladder and salivary gland Naunyn-Schmiedeberg's Arch Pharmacol. 2002, Vol. 366, pages 97-103, abstract *

Also Published As

Publication number	Publication date
US20160002220A1 (en)	2016-01-07
US8853404B2 (en)	2014-10-07
UA95768C2 (ru)	2011-09-12
PL2570128T3 (pl)	2017-09-29
NO20065417L (no)	2006-12-29
CN1976701A (zh)	2007-06-06
EA021994B1 (ru)	2015-10-30
HUE031304T2 (hu)	2017-07-28
KR101152032B1 (ko)	2012-06-11
AU2005237576A1 (en)	2005-11-10
PL1740177T3 (pl)	2012-12-31
BRPI0510170B8 (pt)	2021-05-25
US9144571B2 (en)	2015-09-29
WO2005104745A2 (fr)	2005-11-10
ECSP066940A (es)	2006-12-20
TWI363759B (en)	2012-05-11
US8575347B2 (en)	2013-11-05
EP1740177A4 (fr)	2010-05-05
WO2005104745A3 (fr)	2006-08-03
ES2392848T3 (es)	2012-12-14
CA2755954A1 (fr)	2005-11-10
BE2014C063I2 (fr)	2024-08-08
KR20070015412A (ko)	2007-02-02
CA2564742C (fr)	2012-01-10
MY144753A (en)	2011-10-31
LU92565I9 (fr)	2019-01-17
NZ549997A (en)	2010-10-29
TW200605887A (en)	2006-02-16
EP3111936A1 (fr)	2017-01-04
KR101037026B1 (ko)	2011-05-25
EP2570128A1 (fr)	2013-03-20
SG186597A1 (en)	2013-01-30
EP1740177B1 (fr)	2012-08-08
JP2007534769A (ja)	2007-11-29
US7498440B2 (en)	2009-03-03
ES2600405T3 (es)	2017-02-08
JP5398871B2 (ja)	2014-01-29
CY1113196T1 (el)	2015-12-09
CY1118082T1 (el)	2017-06-28
MA28631B1 (fr)	2007-06-01
US8183257B2 (en)	2012-05-22
HUS1400053I1 (hu)	2017-07-28
US20070249664A1 (en)	2007-10-25
US20140080863A1 (en)	2014-03-20
DK1740177T3 (da)	2012-10-29
BRPI0510170B1 (pt)	2018-12-18
NO338959B1 (no)	2016-11-07
HRP20161385T1 (hr)	2016-12-02
IL178152A (en)	2011-05-31
PT1740177E (pt)	2012-11-02
CA2564742A1 (fr)	2005-11-10
NO2017017I1 (no)	2017-05-04
CA2755954C (fr)	2014-02-18
CY2014043I2 (el)	2015-12-09
EA201100019A1 (ru)	2011-12-30
EA015033B1 (ru)	2011-04-29
US20140371264A1 (en)	2014-12-18
CY2014043I1 (el)	2015-12-09
US9045469B2 (en)	2015-06-02
KR20110010841A (ko)	2011-02-07
US20120157491A1 (en)	2012-06-21
LU92565I2 (fr)	2014-12-02
JP5014121B2 (ja)	2012-08-29
NO2017018I2 (no)	2018-05-14
DK2570128T3 (en)	2016-11-07
UY28871A1 (es)	2005-11-30
AP2006003746A0 (en)	2006-10-31
BRPI0510170A (pt)	2007-10-02
CN102040602A (zh)	2011-05-04
SI2570128T1 (sl)	2016-11-30
HK1102423A1 (en)	2007-11-23
NL300694I1 (fr)	2015-12-29
PE20060259A1 (es)	2006-03-25
ZA200608565B (en)	2019-12-18
AU2005237576B2 (en)	2012-01-12
MXPA06012405A (es)	2007-01-17
EP1740177A2 (fr)	2007-01-10
US8309572B2 (en)	2012-11-13
US7488827B2 (en)	2009-02-10
LT2570128T (lt)	2016-10-10
EP2570128B1 (fr)	2016-08-10
IL178152A0 (en)	2006-12-31
EA200601991A1 (ru)	2007-02-27
JP2012162559A (ja)	2012-08-30
US20150238470A1 (en)	2015-08-27
SI1740177T1 (sl)	2012-12-31
US20130030015A1 (en)	2013-01-31
AR050902A1 (es)	2006-12-06
US20090124653A1 (en)	2009-05-14
HRP20120832T1 (hr)	2012-11-30
PT2570128T (pt)	2016-10-07
ES2392848T4 (es)	2014-10-01
US20070185155A1 (en)	2007-08-09
NL300694I2 (fr)	2015-12-29
NO2017018I1 (no)	2017-05-04

Publication	Publication Date	Title
AP2213A (en)	2011-03-01	Muscarinic acetylcholine receptor antagonists.
IL176775A0 (en)	2006-10-31	Muscarinic acetylcholine receptor antagonists
IL188112A0 (en)	2008-03-20	Muscarinic acetylcholine receptor antagonists
EP1725240A4 (fr)	2009-03-25	Antagonistes du recepteur d'acetylcholine muscarinique
EP1937068A4 (fr)	2010-08-04	Antagonistes de recepteurs d'acetylcholine muscarinique
EP1682142A4 (fr)	2009-11-25	Antagonistes du recepteur muscarinique m3 de l'acetylcholine
ZA200602783B (en)	2007-11-28	Muscarinic acetylcholine receptor antagonists
EP1725238A4 (fr)	2009-04-01	Antagonistes du recepteur muscarinique a l'acetylcholine m 3
EP1937230A4 (fr)	2009-08-26	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1937267A4 (fr)	2009-08-26	Antagonistes des recepteurs de l' acetylcholine muscarinique m3
AP2006003478A0 (en)	2006-02-28	Muscarinic acetylcholine receptor antagonists.
EP1725236A4 (fr)	2009-05-13	Nouveaux antagonistes du recepteur de l'acetylcholine muscarinique m3
IL172911A0 (en)	2006-06-11	Muscarinic acetylcholine receptor antagonists
IL172912A0 (en)	2006-06-11	Muscarinic acetylcholine receptor antagonists
EP1957075A4 (fr)	2009-11-18	Nouveaux antagonistes des recepteurs muscariniques de type m3 de l'acetylcholine
EP1824483A4 (fr)	2009-11-04	Antagonistes des recepteurs de l'acetylcholine muscarinique
EP1749012A4 (fr)	2009-07-29	Antagonistes du recepteur d'acetylcholine muscarinique
EP1827439A4 (fr)	2009-11-18	Nouveaux antagonistes du recepteur d'acetylcholine muscarinique m3
EP1725241A4 (fr)	2009-03-25	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1725564A4 (fr)	2007-09-12	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1765339A4 (fr)	2009-09-02	Antagonistes du recepteur muscarinique d'acetylcholine
EP1781104A4 (fr)	2008-05-21	Antagonistes du recepteur d'acetylcholine muscarinique
EP1781103A4 (fr)	2008-05-14	Antagonistes du recepteur d'acetylcholine muscarinique
EP1751089A4 (fr)	2010-03-10	Nouveaux antagonistes du recepteur d'acetylcholine muscarinique m3
AP2008004537A0 (en)	2008-08-31	Muscarinic receptor antagonists